Clinical observations on controlled-release morphine in cancer pain

Area of Science:

• Oncology
• Pain Management
• Pharmacology

Background:

• Cancer pain significantly impacts patient quality of life.
• Current pain management often involves frequent dosing of oral morphine solutions.
• Optimizing pain relief while minimizing side effects is a clinical priority.

Purpose of the Study:

• To evaluate the analgesic efficacy and side effect profile of controlled-release morphine sulfate tablets for cancer pain.
• To compare the effectiveness and tolerability of controlled-release morphine with immediate-release oral morphine solution.
• To assess the impact of age on dosing requirements for controlled-release morphine.

Main Methods:

• A randomized trial involving 70 advanced cancer pain patients.
• An open-label study with 113 cancer pain patients.
• Assessment of analgesic efficacy, side effects, and dose-response relationships.

Main Results:

• Controlled-release morphine provided analgesia comparable to immediate-release oral morphine solution.
• A statistically significant reduction in certain side effects was observed with controlled-release morphine.
• 91% of patients required controlled-release morphine every 12 hours; 9% required it every 8 hours.

Conclusions:

• Controlled-release morphine sulfate is an effective option for managing cancer pain.
• The controlled-release formulation offers a favorable side effect profile and convenient dosing schedule.
• This formulation can improve patient adherence and quality of life in cancer pain management.